OverviewSuggest Edit

Progenics Pharmaceuticals develops medicines and other technologies to target and treat cancer in the United States and internationally. The Company’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma.
TypePublic
Founded1986
HQNew York, US
Websiteprogenics.com
Employee Ratings2

Latest Updates

Employees (est.) (Dec 2018)79(+24%)
Job Openings3
Revenue (FY, 2018)$15.6 M(+34%)
Share Price (Jun 2019)$4.2 (-1%)

Key People/Management at Progenics Pharmaceuticals

Mark R. Baker

Mark R. Baker

CEO
Pat Fabbio

Pat Fabbio

Senior Vice President and Chief Financial Officer
Vivien Wong

Vivien Wong

Executive Vice President, Development
Aseem Anand

Aseem Anand

Vice President, Digital Technology
Jessica Jensen

Jessica Jensen

Senior Vice President, Clinical Development
Benedict Osorio

Benedict Osorio

Senior Vice President, Quality
Show more

Progenics Pharmaceuticals Office Locations

Progenics Pharmaceuticals has an office in New York
New York, US (HQ)
225 Broadway #630
Show all (1)

Progenics Pharmaceuticals Financials and Metrics

Progenics Pharmaceuticals Revenue

Progenics Pharmaceuticals's revenue was reported to be $15.62 m in FY, 2018
USD

Net income (Q2, 2019)

(19.7m)

EBIT (Q2, 2019)

(19.1m)

Market capitalization (10-Jun-2019)

364.5m

Closing stock price (10-Jun-2019)

4.2

Cash (30-Jun-2019)

84.8m

EV

316.0m
Progenics Pharmaceuticals's current market capitalization is $364.5 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

7.9m8.7m69.4m11.7m15.6m

General and administrative expense

14.8m18.2m23.4m24.9m29.4m

R&D expense

33.9m28.2m37.6m42.6m35.1m

Operating expense total

50.8m48.0m56.3m70.1m82.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

867.0k1.8m1.5m248.0k1.9m1.4m2.5m8.5m53.9m2.3m2.7m3.2m3.9m5.3m4.3m

Cost of goods sold

493.0k

General and administrative expense

3.1m3.9m4.3m3.6m6.0m4.4m5.8m5.6m7.2m5.7m6.0m6.7m7.6m7.1m9.2m14.6m

R&D expense

7.9m6.9m7.8m6.5m6.4m6.8m9.1m8.0m9.8m10.0m10.3m8.1m9.3m8.1m12.4m13.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

65.9m119.3m74.1m138.9m90.6m137.7m

Accounts Receivable

2.9m109.0k3.5m4.9m4.0m3.8m

Inventories

Current Assets

70.7m121.9m83.3m148.1m96.9m144.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

75.6m94.0m85.3m99.3m90.4m65.7m60.1m98.9m126.3m114.0m98.3m83.4m87.5m148.9m109.6m84.8m

Accounts Receivable

754.0k817.0k1.5m1.4m1.5m2.4m3.6m3.9m2.1m2.7m2.6m3.5m3.8m5.8m4.9m10.6m

Current Assets

77.6m97.7m88.8m103.4m97.9m73.2m69.0m106.6m132.1m119.9m102.6m91.8m93.5m156.9m117.6m100.2m

PP&E

2.3m3.7m3.9m4.7m4.6m4.4m3.9m4.1m4.0m6.1m7.0m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(42.6m)4.4m(39.1m)10.7m(51.0m)(67.7m)

Depreciation and Amortization

939.0k545.0k565.0k2.1m1.1m1.5m

Inventories

Accounts Payable

243.0k2.8m(2.9m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(34.0m)(9.3m)(12.3m)(10.3m)(22.0m)(32.0m)(12.7m)(18.3m)18.0m(16.4m)(33.0m)(48.3m)(13.4m)(28.6m)(53.0m)(18.7m)(38.4m)

Depreciation and Amortization

774.0k144.0k318.0k132.0k261.0k398.0k751.0k1.5m1.9m256.0k544.0k832.0k286.0k590.0k1.0m557.0k1.2m

Accounts Payable

1.2m733.0k770.0k402.0k557.0k527.0k(1.8m)(2.8m)(2.7m)124.0k(169.0k)

Cash From Operating Activities

(26.4m)(9.3m)(10.9m)(19.9m)(29.7m)(8.0m)(11.5m)27.3m(12.7m)(25.4m)(41.0m)(14.3m)(25.2m)(37.8m)(18.5m)(38.7m)
USDY, 2019

EV/EBIT

-22.3 x

EV/CFO

-11 x

Financial Leverage

2.1 x
Show all financial metrics

Progenics Pharmaceuticals Online and Social Media Presence

Embed Graph

Progenics Pharmaceuticals News and Updates

Progenics Pharmaceuticals Strengthens Management Team with Appointment of Huw Jones as Vice President, Commercial

-Commercial Leader Brings Deep Experience in Radiopharmaceuticals and Oncology- -Commercial Leader Brings Deep Experience in Radiopharmaceuticals and Oncology-

Velan Releases Detailed Presentation on Progenics Pharmaceuticals

ALPHARETTA, Ga., June 20, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ:PGNX), comprised of successful specialty ...

Progenics Pharmaceuticals Announces Agreement with FUJIFILM Toyama Chemical Co. for Automated Bone Scan Index (aBSI) Product in Japan

aBSI Leverages Artificial Intelligence to Automatically and Reliably Analyze Bone Scan Images from Prostate Cancer Patients aBSI Leverages Artificial Intelligence to Automatically and Reliably Analyze Bone Scan Images from Prostate Cancer Patients

Progenics Pharmaceuticals Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting

NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced today announced that six abstracts highlighting AZEDRA (iobenguane I…

Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration for Prostate Cancer Imaging Agent 1404

Leading Radiopharmaceutical Company ROTOP to Develop and Commercialize Progenics’ PSMA-Targeted SPECT/CT Imaging Agent in Europe Leading Radiopharmaceutical Company ROTOP to Develop and Commercialize Progenics’ PSMA-Targeted SPECT/CT Imaging Agent in Europe

Progenics Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update

NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the first quarter 2019 and provided a business update.
Show more

Progenics Pharmaceuticals Blogs

Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update

Recorded First Revenues for AZEDRA ® ; CMS Grants New Technology Add-On Payment of Up to $98,150 per Therapeutic Dose for Inpatient Use of AZEDRA Enrollment Completed Ahead of Schedule in Phase 3 CONDOR Trial of PyL TM ( 18 F-DCFPyL); Topline Data Expected by Year End 2019 First Patient Dosed in

Progenics Pharmaceuticals Announces Additional Governance Enhancements

Progenics Pharmaceuticals Announces Additional Governance Enhancements Content Import Thu, 08/08/2019 - 08:01 Progenics Pharmaceuticals Announces Additional Governance Enhancements Aug 08, 2019 This release is a backfill from a News Wire …

CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131)

Provides Additional Medicare Reimbursement up to 65% of the Cost of AZEDRA Prescribed for Inpatient Medicare Patients NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence

Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer

Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer Content Import Mon, 08/05/2019 - 08:30 Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer …

Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results and Business Update Call for August 9

Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results and Business Update Call for August 9 Content Import Thu, 08/01/2019 - 08:30 Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results and Business Update Call for August 9 Aug 01, 2019 …

Progenics Pharmaceuticals Announces Collaboration with Veterans Affairs on the AI Research Program for Medical Image Analysis

The collaboration with VA Greater Los Angeles Healthcare System is nation’s first to validate deep learning algorithms in medical imaging of veterans with prostate cancer NEW YORK and WASHINGTON, July 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc.
Show more

Progenics Pharmaceuticals Frequently Asked Questions

  • When was Progenics Pharmaceuticals founded?

    Progenics Pharmaceuticals was founded in 1986.

  • Who are Progenics Pharmaceuticals key executives?

    Progenics Pharmaceuticals's key executives are Mark R. Baker, Pat Fabbio and Vivien Wong.

  • How many employees does Progenics Pharmaceuticals have?

    Progenics Pharmaceuticals has 79 employees.

  • What is Progenics Pharmaceuticals revenue?

    Latest Progenics Pharmaceuticals annual revenue is $15.6 m.

  • What is Progenics Pharmaceuticals revenue per employee?

    Latest Progenics Pharmaceuticals revenue per employee is $197.7 k.

  • Who are Progenics Pharmaceuticals competitors?

    Competitors of Progenics Pharmaceuticals include Karyopharm Therapeutics, TESARO and Clovis Oncology.

  • Where is Progenics Pharmaceuticals headquarters?

    Progenics Pharmaceuticals headquarters is located at 225 Broadway #630, New York.

  • Where are Progenics Pharmaceuticals offices?

    Progenics Pharmaceuticals has an office in New York.

  • How many offices does Progenics Pharmaceuticals have?

    Progenics Pharmaceuticals has 1 office.